Hexarelin is a synthetic six-amino-acid peptide related to GHRP-6 that acts on the ghrelin receptor and triggers growth hormone release. It is not approved as a drug in the US.
Powder vials are usually labeled 2 mg or 5 mg.
Water and syringe-unit charts by vial size: 2 mg · 5 mg
Here is the math for a 2 mg vial mixed with 2 mL of bacteriostatic water, drawing 100 mcg with a U-100 insulin syringe (1 mL = 100 units).
2 mg ÷ 2 mL = 1 mg/mL100 mcg ÷ 1 mg/mL = 0.1 mL0.1 mL × 100 = 10 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 50 mcg | 0.05 mL | 5 units |
| 100 mcg | 0.1 mL | 10 units |
| 200 mcg | 0.2 mL | 20 units |
Adding more water doesn't change how much hexarelin is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 2 mg/mL | 0.05 mL | 5 units |
| 2 mL | 1 mg/mL | 0.1 mL | 10 units |
| 3 mL | 666.7 mcg/mL | 0.15 mL | 15 units |
| 5 mL | 400 mcg/mL | 0.25 mL | 25 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
Human studies of hexarelin are small and short. In six healthy young men, two or three injections under the skin in a day raised growth hormone, but a test dose afterwards gave a smaller growth hormone response and no ACTH or cortisol response, a sign the body adapts to repeated doses. In elderly people, 8 to 15 days of nasal or oral hexarelin kept the growth hormone response but did not raise IGF-1.
Hexarelin also binds a receptor in the heart (CD36), and its effects on the heart and blood vessels have been studied mainly in animals.
We could not find a published human half-life for hexarelin; the pharmacokinetic study we found was in rats, so we do not list one here.